spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamagata, M.
Right arrow Articles by Kimata, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamagata, M.
Right arrow Articles by Kimata, K.

Journal of Cell Science, Vol 107, Issue 9 2581-2590, Copyright © 1994 by Company of Biologists

JOURNAL ARTICLES

Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican

M Yamagata and K Kimata
Institute for Molecular Science of Medicine, Aichi Medical University, Japan.

Malignantly transformed cells usually display a rosette-like morphology of substratum adhesions (called podosomes) and disorganized microfilaments, and are often associated with elevated production of chondroitin sulphate. We previously showed that many tissues and cells express alternatively spliced multiforms of the large chondroitin sulphate proteoglycan termed PG-M (versican is one of the short transcripts). Since PG-M/versican inhibits many types of cell-substratum adhesion and is found to be excluded from focal contacts of cultured fibroblasts, it is likely that this proteoglycan is generally involved in regulating cell-substratum adhesion. We report here that PG-M/versican is selectively excluded from podosomes of human osteosarcoma cells and that specific inhibition of its biosynthesis by an antisense method suppresses such a malignant cell-adhesive phenotype. The results support the idea that PG-M/versican acts as an anti-adhesive molecule and raise the possibility that PG-M/versican controls one type of cancer cell behaviour.


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
H. Koyama, T. Hibi, Z. Isogai, M. Yoneda, M. Fujimori, J. Amano, M. Kawakubo, R. Kannagi, K. Kimata, S. Taniguchi, et al.
Hyperproduction of Hyaluronan in Neu-Induced Mammary Tumor Accelerates Angiogenesis through Stromal Cell Recruitment: Possible Involvement of Versican/PG-M
Am. J. Pathol., March 1, 2007; 170(3): 1086 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Kamiya, H. Watanabe, H. Habuchi, H. Takagi, T. Shinomura, K. Shimizu, and K. Kimata
Versican/PG-M Regulates Chondrogenesis as an Extracellular Matrix Molecule Crucial for Mesenchymal Condensation
J. Biol. Chem., January 27, 2006; 281(4): 2390 - 2400.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Sakko, C. Ricciardelli, K. Mayne, S. Suwiwat, R. G. LeBaron, V. R. Marshall, W. D. Tilley, and D. J. Horsfall
Modulation of Prostate Cancer Cell Attachment to Matrix by Versican
Cancer Res., August 15, 2003; 63(16): 4786 - 4791.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Touab, J. Villena, C. Barranco, M. Arumi-Uria, and A. Bassols
Versican Is Differentially Expressed in Human Melanoma and May Play a Role in Tumor Development
Am. J. Pathol., February 1, 2002; 160(2): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. P. Evanko, J. C. Angello, and T. N. Wight
Formation of Hyaluronan- and Versican-Rich Pericellular Matrix Is Required for Proliferation and Migration of Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1004 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
E. M Culav, C H. Clark, and M. J Merrilees
Connective Tissues: Matrix Composition and Its Relevance to Physical Therapy
Physical Therapy, March 1, 1999; 79(3): 308 - 319.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Zhang, L. Cao, C. G. Kiani, B. L. Yang, and B. B. Yang
The G3 Domain of Versican Inhibits Mesenchymal Chondrogenesis via the Epidermal Growth Factor-like Motifs
J. Biol. Chem., December 4, 1998; 273(49): 33054 - 33063.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. J. Henderson and A. J. Copp
Versican Expression Is Associated With Chamber Specification, Septation, and Valvulogenesis in the Developing Mouse Heart
Circ. Res., September 7, 1998; 83(5): 523 - 532.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Zhang, L. Cao, B. L. Yang, and B. B. Yang
The G3 Domain of Versican Enhances Cell Proliferation via Epidermial Growth Factor-like Motifs
J. Biol. Chem., August 14, 1998; 273(33): 21342 - 21351.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. M. Lemire, S. Potter-Perigo, K. L. Hall, T. N. Wight, and S. M. Schwartz
Distinct Rat Aortic Smooth Muscle Cells Differ in Versican/PG-M Expression
Arterioscler. Thromb. Vasc. Biol., June 1, 1996; 16(6): 821 - 829.
[Abstract] [Full Text]

Home page
 DevelopmentHome page
R. Landolt, L Vaughan, K. Winterhalter, and D. Zimmermann
Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth
Development, January 8, 1995; 121(8): 2303 - 2312.
[Abstract] [PDF]


© The Company of Biologists Ltd 1994